Press release
Currently, 130+ Key Companies are Actively Developing Therapies for the Treatment of Soft Tissue Sarcoma
Soft Tissue Sarcoma Pipeline
The report provides a detailed description of the drug, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any).
The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.
Soft Tissue Sarcoma Pipeline Analysis
The report provides insights into:
The report provides detailed insights about companies that are developing therapies in the Soft Tissue Sarcoma Market.
It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Soft Tissue Sarcoma Treatment.
Soft Tissue Sarcoma key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Soft Tissue Sarcoma Drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Soft Tissue Sarcoma market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Request for Sample PDF: https://www.delveinsight.com/sample-request/soft-tissue-sarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Soft Tissue Sarcoma Therapeutics Analysis
Currently, more than 130+ key companies are developing therapies for Soft Tissue Sarcoma. The companies which have their Soft Tissue Sarcoma drug candidates in the most advanced stage, i.e., phase III, include, Philogen.
Some of the key companies in the Soft Tissue Sarcoma Market include Advenchen Laboratories, Philogen, Gradalis, Epizyme, Eli Lilly and Company, Chugai Pharma France, CytRx, AROG Pharmaceutical, Taiho Pharmaceuticals, NantCell, KaryoPharm Therapeutics, Nanobiotix, Apexigen, Gem Pharmaceuticals, Lytix Biopharma, Novartis, Athenex, Bristol Myers Squibb, Merck Sharp & Dohme, Bristol Myers Squibb, Incyte Corporation, Daiichi Sankyo, AstraZeneca, Pfizer, Merck Sharp & Dohme, NantPharma, Iovance Biotherapeutics, Agenus, Eli Lilly and company, AstraZeneca, Adaptimmune, Aadi, Jiangsu HengRui Medicine, Bayer, Merck, GlaxoSmithKline, AVEO Pharmaceuticals, Amgen, Atara Biotherapeutics, Roche, Bayer, VasGene Therapeutics, Mirati Therapeutics, EMD Serono, AGC Biologics, Novartis, Genor Biopharma, Clovis Oncology, PharmaMar, Boehringer Ingelheim, Morphotek (Eisai), GlaxoSmithKline, Novartis, Incyte Corporation, Tracon Pharmaceuticals, Jiangsu Hengrui Medicine, Exelixis, Sanofi, Pfizer, Merck KGaA, Roche Pharma AG, Bristol-Myers Squibb, Bristol-Myers Squibb, MedImmune, Qbiotics, AstraZeneca, Novartis, AstraZeneca, Aadi, Loxo Oncology, and many others.
Soft Tissue Sarcoma Therapies covered in the report include:
AL3818 (Advenchen Laboratories)
L19 TNF (Philogen)
NBTXR3 (Nanobiotix)
GPX-150 (Monopar Therapeutics)
LTX-315 (Lytix Biopharma)
Nivolumab (Bristol Myers Squibb)
Lenvatinib (Merck sharp & Dohme Corp.)
Durvalumab (AstraZeneca)
Nintedanib (Boehringer Ingelheim)
And many more
Request the Sample PDF to Get a more in-depth Assessment:
https://www.delveinsight.com/report-store/soft-tissue-sarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Table of Content
1. Report Introduction
2. Executive Summary
3. Soft Tissue Sarcoma Current Treatment Patterns
4. Soft Tissue Sarcoma - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Soft Tissue Sarcoma Late Stage Products (Phase-III)
7. Soft Tissue Sarcoma Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Soft Tissue Sarcoma Discontinued Products
13. Soft Tissue Sarcoma Product Profiles
14. Soft Tissue Sarcoma Key Companies
15. Soft Tissue Sarcoma Key Products
16. Dormant and Discontinued Products
17. Soft Tissue Sarcoma Unmet Needs
18. Soft Tissue Sarcoma Future Perspectives
19. Soft Tissue Sarcoma Analyst Review
20. Appendix
21. Report Methodology
*The table of contents is not exhaustive; the final content may vary.
Request for the Sample PDF (to get a detailed understanding of the TOC, Tables, and Figures included in the report), at: https://www.delveinsight.com/report-store/soft-tissue-sarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Contact Info:
Anuj Rawat
Email: info@delveinsight.com
https://www.delveinsight.com/
Request for Sample Copy of the Report at:
https://www.delveinsight.com/sample-request/soft-tissue-sarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Currently, 130+ Key Companies are Actively Developing Therapies for the Treatment of Soft Tissue Sarcoma here
News-ID: 2682950 • Views: …
More Releases from DelveInsight Business Research
Limbal Stem Cell Deficiency Market to Surpass USD 2.6 Billion by 2034, Driven by …
In 2023, the Limbal Stem Cell Deficiency (LSCD) market was dominated by the United States, generating nearly USD 1.5 billion in revenue, while Spain represented the smallest market with approximately USD 127 million. This regional distribution is expected to remain consistent throughout the forecast timeline. The US accounted for nearly 103,000 diagnosed LSCD cases, whereas Japan recorded around 37,000 cases, with both countries projected to witness notable growth in patient…
SSc-ILD Market Set to Cross USD 750 Million by 2034, Driven by 10+ Emerging Ther …
The major players operating in the Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) market include Roche, Prometheus Biosciences, Inc., Merck, GlaxoSmithKline, Genentech, Inc., Acceleron, Boehringer Ingelheim, Actelion, Hôpital Claude-Huriez, Changchun GeneScience Pharmaceutical, among others.
DelveInsight's report titled "Systemic Sclerosis-associated Interstitial Lung Disease Market Insights, Epidemiology, and Forecast-2034" delivers a comprehensive analysis of SSc-ILD, covering historical data, projected epidemiology, and evolving market trends across the United States, EU4 (Germany, Spain, Italy, and France),…
Developmental and Epileptic Encephalopathy Treatment Market Poised for Accelerat …
The Developmental and Epileptic Encephalopathy (DEE) treatment market across the seven major markets (7MM) was valued at nearly USD 2.1 billion in 2023 and is expected to register a healthy compound annual growth rate over the forecast period. The United States emerged as the largest contributor, capturing close to 80% of the overall market revenue.
The DEE treatment landscape is undergoing a significant transformation as the limitations of traditional antiepileptic drugs…
Polycythemia Vera Pipeline and Drug Development in 2025: 10+ Therapies and 8+ Co …
DelveInsight's "Polycythemia Vera Pipeline Insight 2025" report delivers an in-depth overview of the Polycythemia Vera pipeline landscape, covering more than 8 companies and 10+ pipeline candidates. The report analyzes both clinical-stage and preclinical assets, offering detailed drug profiles across various stages of development. It also evaluates Polycythemia Vera therapies based on product classification, development stage, route of administration, and molecular category, while additionally spotlighting inactive or discontinued pipeline assets.
Explore the…
More Releases for Soft
Soft Robotics Grippers Market 2026-2033: Key Trends, Opportunities, and Growth F …
The latest report titled "Soft Robotics Grippers Market" Trends, Share, Size, Growth, Opportunity, and Forecast 2026-2033. offering a comprehensive and in-depth analysis of the industry. The report provides key insights into current market trends, growth drivers, challenges, and opportunities shaping the market landscape. It also includes a thorough competitor analysis, regional market evaluation, and recent technological or strategic developments influencing the market trajectory.
➤ Currently, the Soft Robotics Grippers Market holds…
Soft Robotic Gripper Market Size, Trends Analysis 2033 by Key Vendors- SoftGripp …
USA, New Jersey: According to Verified Market Reports analysis, the global Soft Robotic Gripper Market sizewas valued at USD 1.2 Billion in 2024 and is estimated to reach USD 5.7 Billion by 2033, growing at a CAGR of 18.6% from 2026 to 2033.
How AI and Machine Learning Are Redefining the Future of the Soft Robotic Gripper Market?
AI and machine learning are accelerating a new era of intelligent automation, enabling soft…
Soft Drink Concentrates Market
Introduction
The soft drink concentrates market plays a pivotal role in the global beverage industry. These concentrates are primarily used to prepare soft drinks, offering a cost-effective and efficient way for manufacturers to produce various beverages. Soft drink concentrates are essentially flavored syrups or powders that, when mixed with water or carbonated water, create popular soft drinks. The market for these concentrates has seen remarkable growth in recent years, driven by…
Soft Robot Technology Market Upcoming Trend & Positions 2027 | Cyberdyne, Soft R …
Soft Robot Technology Market Strengths, Weaknesses, Opportunities, and Threats analysis.
Demanding Market Research Report on Global Soft Robot Technology Market conducted by a team of industry specialists. The report covers briefly the products or services in the market and their application. The report also provides data on the technological advancements taking place in the Soft Robot Technology market, helping the market vendors to increase their business productivity and operational efficiency. The…
Soft Skills Management Market - Increasing Demand For Cloud-Based Soft Skill Tra …
According to a new market report published by Transparency Market Research, the global soft skills management market was valued at US$ 11,289.7 Mn in 2016 and is expected to expand at a CAGR of 11.9% from 2018 to 2026, reaching US$ 33,736.1 Mn by the end of the forecast period. According to the report, the global soft skills management market will continue to be influenced by a range of macroeconomic…
Suma Soft
Texas (USA), Canada (Toronto) & India (Business Network)— Suma Soft’s BPO for companies in USA, Canada and UK efficiently streamline business processes. Suma Soft has developed an integrated back-office system that assists these companies giving them round the clock support.
Credibility & Certification :
Suma Soft is an ISO 27001 and 9001 certified company which gives paramount importance to security, accuracy and quality while delivering BPO support services. We have a…
